<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011062</url>
  </required_header>
  <id_info>
    <org_study_id>CDS01</org_study_id>
    <nct_id>NCT01011062</nct_id>
  </id_info>
  <brief_title>Effect of Angiotensin Receptor Blockade on Insulin Resistance and Adipose Tissue Cytokines in Type 2 Diabetes</brief_title>
  <official_title>Effect of Acute Angiotensin Receptor Blockade on Insulin Resistance and Selected Cytokines in Adipose Tissue in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate the effect of acute angiotensin receptor blockade on insulin
      action/insulin resistance and expressions of selected adipocytokines in subcutaneous adipose
      tissue in insulin-resistant subjects with type 2 diabetes and healthy controls.

      Hypothesis: Changes in adipocytokine concentrations and/or expressions and different
      reactions to acute in vivo induced hyperinsulinemia and angiotensin receptor blockade will be
      found in patients with type 2 diabetes compared to healthy subjects. A significant
      relationships between insulin sensitivity and selected adipokines and intracellular fat
      content and high energy phosphates in soleus muscle will be documented in healthy
      individuals, while no significant relation will be found in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      10-15 patients with type 2 diabetes and 10-15 healthy control subjects will be examined on an
      outpatient basis. The following examination will be carried out in each subject after 12 hrs
      fasting:

        -  Oral glucose tolerance test (75 g of glucose) (in healthy subjects to confirm the normal
           tolerance of glucose).

        -  Evaluation of insulin secretion after 1 mg of glucagon i.v.

        -  Hyperinsulinaemic (75 milly-international unit(mIU)/l) euglycemic clamp study lasting 4
           hours combined with indirect calorimetry and biopsy of subcutaneous adipose tissue.

        -  Hyperinsulinemic (75 mIU/l) euglycemic clamp study lasting 4 hours combined with
           indirect calorimetry after losartan 100 mg given in the evening and in the morning
           before the study.

        -  Proton and phosphorus magnetic resonance spectroscopy.

      Before (0 min), at 30 min and in the end of studies c) and d) the blood samples will be taken
      and biopsies of subcutaneous abdominal adipose tissue will be done.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity measured as glucose disposal during clamp</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma adipokines and their expressions in SAT</measure>
    <time_frame>at 0 and 240 min of the clamp</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Hyperinsulinaemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan + hyperinsulinaemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of Saline as a volume control intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperinsulinaemia</intervention_name>
    <description>Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp</description>
    <arm_group_label>Hyperinsulinaemia</arm_group_label>
    <arm_group_label>Losartan + hyperinsulinaemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Acute administration of losartan 200mg total prior to clamp</description>
    <arm_group_label>Losartan + hyperinsulinaemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Infusion of Saline as a volume control intervention</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 Diabetes treated with oral agents and/or diet

          2. Healthy volunteers age- and sex-matched to type 2 diabetes, without any concomitant
             disease

        Exclusion Criteria:

          1. Type 2 Diabetes

               -  treated with insulin

               -  clinical evidence of atherosclerotic complications

               -  advanced long-term diabetic complications (manifest nephropathy, proliferative
                  retinopathy)

               -  other internal disease

               -  weight change &gt;10% 3 months prior to study

          2. Healthy volunteers

               -  fulfilling the criteria of metabolic syndrome

               -  weight change &gt;10% 3 months prior to study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terezie Pelikanova, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Center, Institute of Clinical and Experimental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Center, Institute of Clinical and Experimental Medicine</name>
      <address>
        <city>Prague</city>
        <zip>14021</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>October 17, 2013</last_update_submitted>
  <last_update_submitted_qc>October 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2013</last_update_posted>
  <responsible_party>
    <name_title>Dagmar KÃ¶veslygetyova</name_title>
    <organization>Diabetes Center, Institute for Clinical and Experimental Medicine</organization>
  </responsible_party>
  <keyword>Adipose tissue</keyword>
  <keyword>Adipokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

